- Cytology from thyroid nodule biopsy often shows atypia of undetermined significance (AUS) leading to surgery for ultimately benign histology
- Molecular testing, such as ThyGenX/ThyraMIR, can augment clinical decision-making in thyroid nodule management
- ThyGenX/ThyraMIR testing identifies mutations and provides variable risk of malignancy based on genotype and miRNA expression profile
- ThyGenX assesses common genetic alterations across 8 genes associated with papillary and follicular carcinoma
- ThyraMIR is a miRNA gene expression classifier based on evaluation of expression of 10 short, non-coding miRNAs that regulate translation
- This project examined ThyGenX/ThyraMIR testing of thyroid nodules in the San Antonio Military Health System (SAMHS)
Show Me The Money! Institutional Experience with Molecular Testing of Thyroid Nodules
ATA 2018, Washington, DC
